Cargando…
The effect of tenofovir on renal function in HIV-positive pregnant women
INTRODUCTION: Tenofovir is a commonly used component of antiretroviral therapy (ART) to reduce vertical transmission of HIV. Although systematic review of tenofovir use in pregnancy concluded it to be low risk for foetal abnormalities [1], data is limited on its impact on renal function in pregnant...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International AIDS Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225428/ https://www.ncbi.nlm.nih.gov/pubmed/25397444 http://dx.doi.org/10.7448/IAS.17.4.19694 |
_version_ | 1782343505041948672 |
---|---|
author | Flanagan, Stuart Barnes, Lynne Anderson, Jane Barber, Tristan |
author_facet | Flanagan, Stuart Barnes, Lynne Anderson, Jane Barber, Tristan |
author_sort | Flanagan, Stuart |
collection | PubMed |
description | INTRODUCTION: Tenofovir is a commonly used component of antiretroviral therapy (ART) to reduce vertical transmission of HIV. Although systematic review of tenofovir use in pregnancy concluded it to be low risk for foetal abnormalities [1], data is limited on its impact on renal function in pregnant women. A recent South African study [2] concluded that renal dysfunction in HIV-infected pregnant women is significantly less common than in other HIV-infected adults, however there is currently no UK data. We aimed to investigate the effect of tenofovir on renal function in HIV-1 positive pregnant women in a UK clinic. METHODS: We retrospectively analyzed data on renal function in pregnancy from a cohort of women attending a busy inner city London antenatal clinic. All women were screened for renal function throughout pregnancy via serum creatinine and estimated glomerular filtration rate (eGFR) calculated using modification of diet in renal disease (MDRD) and corrected for ethnicity. RESULTS: Ninety-seven HIV-1 positive women were registered at Homerton Hospital antenatal service of a total of 105 pregnancies between January 2010 and September 2013. Tenofovir was prescribed in 71/105 pregnancies (67.6%). Of the 71 pregnancies, 41 were prescribed tenofovir pre-conception (57.7%). Of the pregnant women who started tenofovir in pregnancy, 21/31 (67.7%) were initiated before week 24 of pregnancy, in line with British HIV association (BHIVA) guidelines [3]. There was no deterioration in median serum creatinine or decline in eGFR in women prescribed tenofovir during pregnancy. At six weeks after delivery, in the 42 women who continued tenofovir therapy and had eGFR measured, one woman had eGFR=60, all others eGFR >90 (Table 1). CONCLUSIONS: Consistent with current guidelines and experience, this study shows tenofovir did not cause decline in renal function in pregnancy in our cohort of HIV-1 positive women, whether started during pre-conception or during pregnancy. More evidence should be prospectively collected looking at effects of tenofovir on other measures of tubular renal function in pregnancy such as proteinuria and protein-creatinine ratio. |
format | Online Article Text |
id | pubmed-4225428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | International AIDS Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-42254282014-11-13 The effect of tenofovir on renal function in HIV-positive pregnant women Flanagan, Stuart Barnes, Lynne Anderson, Jane Barber, Tristan J Int AIDS Soc Poster Sessions – Abstract P162 INTRODUCTION: Tenofovir is a commonly used component of antiretroviral therapy (ART) to reduce vertical transmission of HIV. Although systematic review of tenofovir use in pregnancy concluded it to be low risk for foetal abnormalities [1], data is limited on its impact on renal function in pregnant women. A recent South African study [2] concluded that renal dysfunction in HIV-infected pregnant women is significantly less common than in other HIV-infected adults, however there is currently no UK data. We aimed to investigate the effect of tenofovir on renal function in HIV-1 positive pregnant women in a UK clinic. METHODS: We retrospectively analyzed data on renal function in pregnancy from a cohort of women attending a busy inner city London antenatal clinic. All women were screened for renal function throughout pregnancy via serum creatinine and estimated glomerular filtration rate (eGFR) calculated using modification of diet in renal disease (MDRD) and corrected for ethnicity. RESULTS: Ninety-seven HIV-1 positive women were registered at Homerton Hospital antenatal service of a total of 105 pregnancies between January 2010 and September 2013. Tenofovir was prescribed in 71/105 pregnancies (67.6%). Of the 71 pregnancies, 41 were prescribed tenofovir pre-conception (57.7%). Of the pregnant women who started tenofovir in pregnancy, 21/31 (67.7%) were initiated before week 24 of pregnancy, in line with British HIV association (BHIVA) guidelines [3]. There was no deterioration in median serum creatinine or decline in eGFR in women prescribed tenofovir during pregnancy. At six weeks after delivery, in the 42 women who continued tenofovir therapy and had eGFR measured, one woman had eGFR=60, all others eGFR >90 (Table 1). CONCLUSIONS: Consistent with current guidelines and experience, this study shows tenofovir did not cause decline in renal function in pregnancy in our cohort of HIV-1 positive women, whether started during pre-conception or during pregnancy. More evidence should be prospectively collected looking at effects of tenofovir on other measures of tubular renal function in pregnancy such as proteinuria and protein-creatinine ratio. International AIDS Society 2014-11-02 /pmc/articles/PMC4225428/ /pubmed/25397444 http://dx.doi.org/10.7448/IAS.17.4.19694 Text en © 2014 Flanagan S et al; licensee International AIDS Society http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Poster Sessions – Abstract P162 Flanagan, Stuart Barnes, Lynne Anderson, Jane Barber, Tristan The effect of tenofovir on renal function in HIV-positive pregnant women |
title |
The effect of tenofovir on renal function in HIV-positive pregnant women |
title_full |
The effect of tenofovir on renal function in HIV-positive pregnant women |
title_fullStr |
The effect of tenofovir on renal function in HIV-positive pregnant women |
title_full_unstemmed |
The effect of tenofovir on renal function in HIV-positive pregnant women |
title_short |
The effect of tenofovir on renal function in HIV-positive pregnant women |
title_sort | effect of tenofovir on renal function in hiv-positive pregnant women |
topic | Poster Sessions – Abstract P162 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225428/ https://www.ncbi.nlm.nih.gov/pubmed/25397444 http://dx.doi.org/10.7448/IAS.17.4.19694 |
work_keys_str_mv | AT flanaganstuart theeffectoftenofovironrenalfunctioninhivpositivepregnantwomen AT barneslynne theeffectoftenofovironrenalfunctioninhivpositivepregnantwomen AT andersonjane theeffectoftenofovironrenalfunctioninhivpositivepregnantwomen AT barbertristan theeffectoftenofovironrenalfunctioninhivpositivepregnantwomen AT flanaganstuart effectoftenofovironrenalfunctioninhivpositivepregnantwomen AT barneslynne effectoftenofovironrenalfunctioninhivpositivepregnantwomen AT andersonjane effectoftenofovironrenalfunctioninhivpositivepregnantwomen AT barbertristan effectoftenofovironrenalfunctioninhivpositivepregnantwomen |